Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $2K fell 71.4% year over year, behind the -52.3% change in trailing-twelve-month revenue. Sequentially, it fell 66.7% from the prior quarter. Over 3 fiscal years it compounded at -92.5% a year.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $12.88K (-64.2%) for the fiscal year ending Dec 2026, a slowdown from the -41.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2K-66.7% QoQ
Last fiscal yearDec 2025
$36K-41.0% YoY
LTMMar 2026
$31K-52.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.4%-54.7%+16.7 pp
1 year-41.0%-64.2%-23.3 pp
3-year CAGR-92.5%+979.0%+1071.5 pp
5-year CAGR+511.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
36K USD
Year-over-year change
-41.0%
4-year CAGR
-75.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -52.3% is the 3rd highest of 4, against a peer median of +0.3%.
  • Over three fiscal years its annual growth of -92.5% compares with a peer median of -16.7%.
LYEL Competitors
Revenue for LYEL and competitors
Company Period LTM YoY 3-year CAGR
AMRNAmarin Corporation plcLTM Mar 2026$214.88M USD+0.3%-16.7%
EDITEditas Medicine, Inc.LTM Mar 2026$38.69M USD+8.0%+27.1%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%
SLNSilence Therapeutics plcLTM Mar 2026$921.49K USD—-68.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026$31K USD-52.3%-92.5%
GNLXGenelux CorporationLTM Mar 2026$8K USD—-91.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$0 USD——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD——
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding LYEL) —+0.3%-16.7%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.